dr. ezra cohen on the efficacy and pharmacokinetics of cabozantinib
Published 11 years ago • 571 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
1:16
dr. ezra cohen discusses the cabozantinib dose size and tolerability
-
0:59
dr. ezra cohen discusses the cabozantinib exam trial
-
1:15
dr. cohen on mtor inhibition in head and neck cancer
-
2:07
dr. cohen on challenges with immunotherapy in head and neck cancer
-
1:34
dr. eric sherman on the sequencing of cabozantinib and vandetanib for mtc
-
1:45
dr. vogelzang discusses cabozantinib's dose size
-
0:56
dr. vogelzang on cabozantinib clinical trial results
-
1:00
dr. cohen on biomarker testing in head and neck cancer
-
0:46
dr. pecora on the pathway inhibitor cabozantinib
-
1:59
dr. cohen discusses promise of immunotherapy in head and neck cancer
-
1:34
dr. vogelzang discusses the cabozantinib trial design
-
5:34
pembrolizumab for recurrent hnscc
-
1:14
dr. vogelzang describes cabozantinib's side effects
-
1:35
dr. vogelzang discusses cabozantinib trial design
-
1:36
dr. vogelzang discusses mortalities in cabozantinib trial
-
47:05
immunotherapy in head and neck cancer: prof. ezra cohen
-
1:43
dr. ghassan abou-alfa on met inhibition with tivantinib and cabozantinib in liver cancer
-
0:57
dr. tolaney on trials investigating cabozantinib in breast cancer
-
0:52
dr. harvey on aromatase inhibitor treatment duration